Johnson & Johnson's Ethicon Biosurgery gained the FDA's blessing for a new device designed to stop otherwise-uncontrollable bleeding during surgical procedures. The regulatory win comes after a tough period of recalls and lawsuits for the larger division.
Partnered with J&J in a major market deal, Pharmacyclics demonstrated fresh evidence that ibrutinib could control malignancies in patients who were both treatment naïve and unresponsive to other meds.
Diagnosing and treating Alzheimer's disease has been one of the big scientific mysteries of the past generation. But even without a full understanding, or even scientific consensus, on what causes the disease, the prospect of earning $9 billion to $10 billion a year for a drug that can even modestly ameliorate a terrible disease afflicting millions of people has kept investigators in the game.
In Australia, at least, Johnson & Johnson's ($JNJ) beleaguered DePuy unit is coming to some resolution regarding poorly made joint replacements. A judge there has approved a settlement for patients who sued over defective knee implants.
Johnson & Johnson has scored a partial court victory in its long-running battle over the antibiotic Levaquin. The drugmaker has faced thousands of lawsuits claiming Levaquin caused tendon injuries--and that J&J didn't do enough to warn patients and doctors of the risk.
Alex Gorsky now has it all. The CEO of Johnson & Johnson today was named chairman of the drug and consumer products company, replacing Bill Weldon, who is retiring from J&J after four decades.
Johnson & Johnson's Janssen has taken a step closer to gaining approval for the first new way of combating tuberculosis in decades. And an FDA advisory committee voted 18-0 in favor of efficacy of the experimental med, bedaquiline, for combating multidrug-resistant cases of the infection.
Now more than ever, medical device and diagnostics companies can't avoid a simple truth: China is a crucial ingredient for their growth and future. And they're embracing that reality with a vengeance.
An influential group of industry critics has reshuffled its listing of Big Pharma companies, lauding some big players like Johnson & Johnson for improving access to therapies and promoting R&D on neglected diseases while handing out worsening grades to many others. And the entire industry earned a black eye for outsourcing more of their drug development efforts without safeguards to make sure the work being done for them is safe and ethical.
Here's some good news for Big Pharma's image: The latest Access to Medicine Index shows that major drugmakers are doing a better job of getting their products into the hands of patients in poor countries. Since the last report two years ago, some companies have clearly stepped up their game.